The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2021 | Predictive value of 18F-FDG-PET radiomics in R/R Hodgkin lymphoma
Julia Driessen, MBBS, University of Amsterdam, Amsterdam, The Netherlands, outlines the predictive value of quantitative 18F-FDG-PET radiomics analysis in patients with relapsed/refractory (R/R) Hodgkin lymphoma. Baseline 18F-FDG-PET was analyzed from R/R classical Hodgkin lymphoma patients from three clinical trials of ICE (ifosfamide-carbplatin-etoposide), ICE plus brentuximab vedotin (BV) or DHAP (dexamethasone-high-dose cytarabine-platinum) and BV. The study reported that the combination of 18F-FDG-PET radiomics and clinical features was able to make a strong prediction model for three-year time to progression and could be used to guide risk-stratified treatment in R/R classical Hodgkin lymphoma. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
